Key highlights
•Recruitment is well advanced for the BTX 1801 Phase 2a clinical study to evaluate the safety, tolerability and efficacy of BTX 1801 as a nasal decolonisation agent for Staph and MRSA
•Completion of a successful End of Phase 2 meeting for BTX 1503 for acne with the FDA
•BTX 1702 study is poised to commence recruitment once travel and clinical trial conduct restrictions are eased in Australia and New Zealand
•Botanix remains in a strong financial position, holding cash balance of A$22.1m as at 30 September 2020
Ann: Appendix 4C - Quarterly, page-2
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.5¢ |
Change
0.015(4.05%) |
Mkt cap ! $699.7M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 39.0¢ | 37.0¢ | $1.537M | 4.028M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 91664 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.5¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |